Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

FDG-PET CT in the evaluation of primary and secondary pancreatic malignancies.

Bohl CE, Federico SM, Robinson GW, Bahrami A, Shulkin BL.

Pediatr Blood Cancer. 2018 Oct;65(10):e27115. doi: 10.1002/pbc.27115. Epub 2018 May 11.

PMID:
29750397
2.

Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen.

Kim J, Coss CC, Barrett CM, Mohler ML, Bohl CE, Li CM, He Y, Veverka KA, Dalton JT.

Int J Cancer. 2013 Mar 15;132(6):1475-85. doi: 10.1002/ijc.27794. Epub 2012 Sep 14.

3.

The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.

Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS.

J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):153-161. Epub 2011 Aug 2.

4.

Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets.

Duke CB, Jones A, Bohl CE, Dalton JT, Miller DD.

J Med Chem. 2011 Jun 9;54(11):3973-6. doi: 10.1021/jm2000097. Epub 2011 May 16.

PMID:
21506597
5.

Cancer cachexia therapy: a key weapon in the fight against cancer.

Coss CC, Bohl CE, Dalton JT.

Curr Opin Clin Nutr Metab Care. 2011 May;14(3):268-73. doi: 10.1097/MCO.0b013e3283455e21. Review.

PMID:
21415732
6.

Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer.

Narayanan R, Yepuru M, Szafran AT, Szwarc M, Bohl CE, Young NL, Miller DD, Mancini MA, Dalton JT.

Cancer Res. 2010 Jan 15;70(2):842-51. doi: 10.1158/0008-5472.CAN-09-3206. Epub 2010 Jan 12.

7.

Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.

Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, Dalton JT, Miller DD.

J Med Chem. 2009 Jun 25;52(12):3597-617. doi: 10.1021/jm900280m. Review. No abstract available.

PMID:
19432422
8.

Selective androgen receptor modulators in preclinical and clinical development.

Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT.

Nucl Recept Signal. 2008;6:e010. doi: 10.1621/nrs.06010. Epub 2008 Nov 26. Review.

9.

Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators.

Bohl CE, Wu Z, Chen J, Mohler ML, Yang J, Hwang DJ, Mustafa S, Miller DD, Bell CE, Dalton JT.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5567-70. doi: 10.1016/j.bmcl.2008.09.002. Epub 2008 Sep 5.

11.

Domain structure and DNA binding regions of beta protein from bacteriophage lambda.

Wu Z, Xing X, Bohl CE, Wisler JW, Dalton JT, Bell CE.

J Biol Chem. 2006 Sep 1;281(35):25205-14. Epub 2006 Jul 3.

12.

Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer.

Yang J, Bohl CE, Nair VA, Mustafa SM, Hong SS, Miller DD, Dalton JT.

J Pharmacol Exp Ther. 2006 Apr;317(1):402-8. Epub 2006 Jan 24.

PMID:
16434567
13.

Characterization of the in vitro metabolism of selective androgen receptor modulator using human, rat, and dog liver enzyme preparations.

Gao W, Wu Z, Bohl CE, Yang J, Miller DD, Dalton JT.

Drug Metab Dispos. 2006 Feb;34(2):243-53. Epub 2005 Nov 4.

14.

In vitro and in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring.

Chen J, Hwang DJ, Chung K, Bohl CE, Fisher SJ, Miller DD, Dalton JT.

Endocrinology. 2005 Dec;146(12):5444-54. Epub 2005 Sep 15.

15.

Chemistry and structural biology of androgen receptor.

Gao W, Bohl CE, Dalton JT.

Chem Rev. 2005 Sep;105(9):3352-70. Review. No abstract available.

16.

Structural basis for accommodation of nonsteroidal ligands in the androgen receptor.

Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT.

J Biol Chem. 2005 Nov 11;280(45):37747-54. Epub 2005 Aug 29.

17.

Structural basis for antagonism and resistance of bicalutamide in prostate cancer.

Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT.

Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6201-6. Epub 2005 Apr 15.

18.

A selective androgen receptor modulator for hormonal male contraception.

Chen J, Hwang DJ, Bohl CE, Miller DD, Dalton JT.

J Pharmacol Exp Ther. 2005 Feb;312(2):546-53. Epub 2004 Sep 3.

PMID:
15347734
19.

A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor.

Bohl CE, Chang C, Mohler ML, Chen J, Miller DD, Swaan PW, Dalton JT.

J Med Chem. 2004 Jul 15;47(15):3765-76.

Supplemental Content

Support Center